EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EBV DNAemia After Solid Organ Transplant: Risk Stratification, Monitoring, Treatment and Progression to Post-Transplant Lymphoproliferative Disorder

Cassandra Duarte, Bradley Haverkos

Viruses · 17.11.2026 · 18 (11) · 1276

DOI: 10.3390/v18111276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 17.11.2026. Verfasst von Cassandra Duarte und 1 weiteren Autor:innen. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein–Barr virus (EBV) is a nearly ubiquitous oncogenic virus that drives the development of post-transplant lymphoproliferative disorder (PTLD) in solid organ-transplant (SOT) recipients through B-lymphocyte infection and disruption of normal apoptotic and immune-surveillance pathways. This review synthesizes current evidence on the relationship between EBV DNAemia and PTLD, demonstrating that elevated whole blood or plasma EBV viral loads may precede and help identify patients at increased risk of EBV+ PTLD, though testing methodology and timing remain unstandardized across studies. EBV DNAemia is associated with increased risk of PTLD, particularly in high-risk serostatus and heavily immunosuppressed recipients. However, differences in specimen types, assay methodologies, and intervention thresholds currently limit predictive precision and standardization of preemptive management. Frontline management of EBV DNAemia follows a stepwise approach beginning with reduced immunosuppression, escalating to rituximab and sequential chemoimmunotherapy as needed if PTLD develops. For relapsed or refractory EBV-positive disease, emerging EBV-directed cellular therapies show meaningful survival benefit over historical outcomes. Novel biomarkers for EBV may include soluble ZEBRA protein assessment, EBV DNA methylation, and LMP1 mutation status, in addition to CMV DNAemia. There remains an urgent unmet need for standardized, prospective, multicenter studies to define optimal EBV monitoring strategies and guide preemptive intervention in this high-risk population.

Zitieren

APA

Duarte, C., & Haverkos, B. (2026). EBV DNAemia After Solid Organ Transplant: Risk Stratification, Monitoring, Treatment and Progression to Post-Transplant Lymphoproliferative Disorder. Viruses, 18(11), 1276. https://doi.org/10.3390/v18111276

Vancouver

Duarte C, Haverkos B. EBV DNAemia After Solid Organ Transplant: Risk Stratification, Monitoring, Treatment and Progression to Post-Transplant Lymphoproliferative Disorder. Viruses. 2026;18(11):1276. doi:10.3390/v18111276

BibTeX
@article{Duarte2026,
  author = {Duarte, Cassandra and Haverkos, Bradley},
  title = {EBV DNAemia After Solid Organ Transplant: Risk Stratification, Monitoring, Treatment and Progression to Post-Transplant Lymphoproliferative Disorder},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1276},
  doi = {10.3390/v18111276}
}
Kostenlos starten →